X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/03/27/2852892/0/en/Santhera-Announces-NDA-for-Vamorolone-in-Duchenne-Muscular-Dystrophy-Accepted-and-Granted-Priority-Review-by-China-s-NMPA.html
https://www.globenewswire.com//news-release/2024/03/14/2845975/0/en/Santhera-s-Partner-Catalyst-Pharmaceuticals-Launches-AGAMREE-Vamorolone-in-the-United-States.html
https://www.globenewswire.com//news-release/2024/02/21/2832813/13009/en/Catalyst-Pharmaceuticals-Announces-Publication-of-Santhera-Pharmaceutical-s-VISION-DMD-Vamorolone-AGAMREE-Study-Results-in-the-Peer-Reviewed-Journal-Neurology.html
https://www.globenewswire.com//news-release/2024/02/14/2828764/0/en/Santhera-Announces-Publication-of-Efficacy-Safety-and-Tolerability-Data-with-Vamorolone-AGAMREE-in-Patients-with-Duchenne-Muscular-Dystrophy-in-Neurology.html
https://www.globenewswire.com//news-release/2024/01/15/2808933/0/en/Santhera-Launches-AGAMREE-Vamorolone-in-Germany-as-First-Market-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2024/01/12/2808425/0/en/Santhera-Receives-Approval-for-AGAMREE-Vamorolone-as-a-Treatment-for-Duchenne-Muscular-Dystrophy-in-the-United-Kingdom.html
https://www.globenewswire.com//news-release/2023/12/18/2797461/0/en/Santhera-s-AGAMREE-Vamorolone-Approved-in-the-European-Union-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2023/10/27/2768135/0/en/Santhera-Receives-U-S-FDA-Approval-of-AGAMREE-vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2023/10/13/2759744/0/en/Santhera-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-AGAMREE-vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2023/07/19/2707116/13009/en/Catalyst-Pharmaceuticals-Acquires-Exclusive-North-American-License-For-Vamorolone-for-Duchenne-Muscular-Dystrophy-from-Santhera-Pharmaceuticals.html
https://www.globenewswire.com/news-release/2023/07/19/2706971/0/en/Santhera-Announces-Closing-of-Exclusive-North-America-License-Agreement-with-Catalyst-Pharmaceuticals-for-Vamorolone.html
https://www.pharmaceutical-technology.com/news/catalyst-santhera-vamorolone/
https://www.globenewswire.com/news-release/2023/06/20/2690702/0/en/Santhera-Grants-Exclusive-North-America-License-for-Vamorolone-to-Catalyst-Pharmaceuticals-in-Deal-Valued-at-up-to-USD-231-Million-Plus-Royalties.html
https://www.globenewswire.com/news-release/2023/06/20/2690858/13009/en/Catalyst-Pharmaceuticals-to-License-North-American-Rights-to-Vamorolone-for-Duchenne-Muscular-Dystrophy-from-Santhera-Pharmaceuticals.html
https://www.globenewswire.com/news-release/2023/01/09/2584775/0/en/Santhera-and-ReveraGen-Announce-FDA-Acceptance-of-New-Drug-Application-for-Vamorolone-in-Duchenne-Muscular-Dystrophy.html
https://pharmaphorum.com/news/santhera-seeks-speedy-fda-review-of-duchenne-drug-vamorolone/
https://www.pharmatimes.com/news/santhera_submits_marketing_authorisation_application_for_vamorolone_1456225
https://www.globenewswire.com/news-release/2022/10/03/2526460/0/en/Santhera-Submits-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-Vamorolone-in-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2022/09/01/2508149/0/en/JAMA-Neurology-Publishes-Positive-Pivotal-Clinical-Trial-with-Vamorolone-in-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2022/08/22/2501855/0/en/Santhera-and-ReveraGen-Announce-First-Participant-Dosed-in-FDA-funded-Phase-2-Pilot-Study-with-Vamorolone-in-Becker-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2022/06/29/2470898/0/en/Santhera-Updates-on-Ongoing-NDA-Submission-for-Vamorolone.html
https://www.globenewswire.com/news-release/2022/03/15/2403031/0/en/Santhera-and-ReveraGen-to-Present-Efficacy-and-Safety-Data-with-Vamorolone-at-2022-Muscular-Dystrophy-Association-Conference.html
https://www.globenewswire.com/news-release/2022/01/04/2360381/0/en/Santhera-Enters-into-Exclusive-License-Agreement-with-Sperogenix-for-Vamorolone-in-Rare-Diseases-in-the-Greater-China-Region.html
https://www.globenewswire.com/news-release/2021/11/23/2339468/0/en/Santhera-and-ReveraGen-Announce-Positive-Topline-Results-with-Vamorolone-after-Completion-of-the-VISION-DMD-Study.html
https://www.globenewswire.com/news-release/2021/11/17/2335970/0/en/Santhera-and-ReveraGen-Announce-Successful-FDA-Pre-NDA-Meeting-for-Vamorolone-in-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2021/11/17/2335970/0/de/Santhera-und-ReveraGen-geben-erfolgreiches-FDA-Pre-NDA-Meeting-f%C3%BCr-Vamorolone-in-Duchenne-Muskeldystrophie-bekannt.html
https://www.globenewswire.com/news-release/2020/09/14/2092669/0/en/Santhera-Announces-Publication-on-Molecular-Distinctions-of-Vamorolone-Compared-to-Corticosteroids.html
https://www.globenewswire.com/news-release/2020/09/02/2087402/0/en/Santhera-Exercises-Option-to-Obtain-Worldwide-Rights-to-Vamorolone-in-Duchenne-Muscular-Dystrophy-and-All-Other-Indications.html
https://www.globenewswire.com/news-release/2020/06/02/2041887/0/en/Santhera-Announces-Completion-of-ReveraGen-s-Long-Term-Extension-Study-with-Vamorolone-in-Duchenne-Muscular-Dystrophy.html#:~:text=Pratteln%2C%20Switzerland%2C%20June%202%2C,Duchenne%20muscular%20dystrophy%20(DMD).
https://www.biospace.com/article/reveragen-s-vamorolone-demonstrates-improvement-in-muscular-dystrophy/
https://endpts.com/santheras-duchenne-effort-gets-a-boost-on-positive-phiia-for-alternative-steroid-vamorolone/
https://www.clinicaltrialsarena.com/news/positive-data-vamorolone-dmd/
https://www.fiercebiotech.com/biotech/idorsia-sheds-surplus-dmd-therapy-to-santhera
Market Place
Share 
